One To Watch

KalVista Pharmaceuticals

Clinical-stage biotech developing oral therapies for hereditary angioedema, with sebetralstat in late-stage development. KalVista agreed in April 2026 to be acquired by Italian pharma Chiesi to expand its rare disease portfolio.

Company Overview

A clinical-stage biopharmaceutical company developing oral small molecule protease inhibitors for rare diseases, with hereditary angioedema as its lead indication and a heritage rooted in ophthalmology research. KalVista builds novel protease inhibitor programs through preclinical and clinical development, targeting diseases with significant unmet medical need. The company's strategic ambition centers on transforming the patient experience by replacing injectable or infusion-based therapies with convenient oral alternatives. Its pipeline, anchored in hereditary angioedema, positions KalVista as a specialist in rare disease oral therapy development.

Headquarters and Global Presence

KalVista is headquartered in Framingham, Massachusetts, and retains scientific roots in Southampton, UK, where the company was originally founded. The organization employs approximately 270 full-time staff across its US and UK operations, supporting clinical, regulatory, and research functions.

Founding and History

KalVista was founded in the United Kingdom and initially launched with £8 million in Series A financing from Novo A/S and SV Life Sciences to develop therapies for diabetic macular edema. The company subsequently shifted strategic focus toward rare diseases, particularly hereditary angioedema, and relocated its primary corporate base to the United States. KalVista trades on Nasdaq under the ticker KALV. In April 2026, Italian specialty pharma group Chiesi announced an agreement to acquire KalVista, adding the company's rare disease portfolio to Chiesi's expanding pipeline.

Therapy Areas and Focus

KalVista's primary therapeutic focus is hereditary angioedema, a rare and potentially life-threatening condition caused by dysregulation of the plasma kallikrein-bradykinin pathway that produces unpredictable, recurrent swelling attacks. The standard of care has long relied on injectable or intravenous therapies, creating a substantial unmet need for oral on-demand and prophylactic options. KalVista targets the plasma kallikrein enzyme as the key mechanistic node, seeking to deliver effective attack prevention and treatment through well-tolerated oral small molecules. The company's earlier work in diabetic macular edema, another condition driven by kallikrein pathway activity, informed its protease inhibitor chemistry and platform expertise.

Technology Platforms and Modalities

KalVista's core platform is the design and optimization of oral, small molecule inhibitors of plasma kallikrein, a serine protease central to contact activation and bradykinin generation. By blocking kallikrein activity, the company's compounds interrupt the downstream release of bradykinin, the mediator responsible for vascular permeability and angioedema swelling. The small molecule approach offers inherent advantages over injectable biologics, including oral bioavailability, ambient storage, and greater patient autonomy. KalVista applies structure-based drug design and medicinal chemistry expertise to achieve potency, selectivity, and pharmacokinetic profiles suitable for both on-demand attack treatment and daily prophylaxis.

Key Pipeline and Programs

Sebetralstat is KalVista's most advanced asset, an oral plasma kallikrein inhibitor developed for on-demand treatment of acute HAE attacks. The compound advanced through Phase III evaluation in the KONFIDENT trial, a global, randomized, placebo-controlled study assessing time to symptom relief and attack severity in patients experiencing acute attacks. Sebetralstat represented the first oral on-demand therapy candidate to reach Phase III in HAE, a meaningful differentiator in a space dominated by subcutaneous and intravenous treatments. KVD824 is KalVista's oral prophylaxis program, also targeting plasma kallikrein, designed for once-daily dosing to reduce attack frequency in HAE patients. KVD824 entered clinical development as a longer-acting companion to sebetralstat, with the two programs together addressing both the acute and preventive dimensions of HAE management. Earlier-stage work continues in the ophthalmic space, building on the company's foundational DME research with plasma kallikrein inhibitors administered intravitreally.

Recent Developments

The most significant recent development is the April 2026 announcement that Chiesi Farmaceutici will acquire KalVista Pharmaceuticals, adding KalVista's oral HAE pipeline to Chiesi's rare disease portfolio in a transaction that underscores the strategic value of the company's protease inhibitor franchise. The acquisition reflects growing industry appetite for differentiated oral rare disease assets, particularly in HAE where the market is transitioning away from injectables. Prior to the deal announcement, KalVista had been advancing sebetralstat through late-stage clinical evaluation and engaging with regulatory agencies on its development path.

Key Personnel

Marc Eggerickx serves as President and Chief Executive Officer, bringing rare disease drug development and commercial leadership experience to KalVista's late-stage operations. Andrew Crockett, one of the company's founding figures, played a central role in establishing the protease inhibitor platform and guiding the strategic pivot from ophthalmology to rare disease. The leadership team has built KalVista from a UK-based ophthalmology startup into a Nasdaq-listed clinical-stage rare disease company now set to become part of Chiesi's global portfolio.

Strategic Partnerships

KalVista's most consequential strategic transaction is the pending acquisition by Chiesi Farmaceutici, announced in April 2026, which will integrate KalVista's oral HAE programs into Chiesi's rare disease division. The company's early development was funded by Novo A/S and SV Life Sciences, whose backing established KalVista's scientific and financial foundation. These relationships reflect a progression from venture-backed startup to acquisition target, driven by the clinical maturation of the sebetralstat program.

FAQ Section

Chiesi's April 2026 decision to acquire KalVista reflects the rising commercial value of oral therapies in hereditary angioedema, a market historically served by injectable biologics such as subcutaneous lanadelumab and intravenous icatibant. Sebetralstat, as the first oral on-demand HAE treatment to reach Phase III, represents a potentially transformative convenience advance for patients. The deal confirms that established rare disease companies are willing to pay for late-stage oral protease inhibitor assets as the HAE treatment landscape evolves.

Hereditary angioedema type I and II arises from deficiency or dysfunction of C1-esterase inhibitor, the natural brake on the contact activation pathway, leading to uncontrolled plasma kallikrein activity and excessive bradykinin production. Bradykinin binds B2 receptors on vascular endothelium, causing the vasodilation and fluid extravasation that produce swelling attacks in the skin, gastrointestinal tract, and airway. Inhibiting plasma kallikrein directly addresses the proximal enzymatic driver of these attacks, offering mechanistic specificity that translates well into small molecule drug design.

Approved HAE therapies, including subcutaneous lanadelumab for prophylaxis and injectable icatibant or intravenous C1-inhibitor replacement for acute attacks, require administration by injection or infusion, creating logistical and psychological burdens for patients. KalVista's sebetralstat is an oral tablet taken at the onset of an attack, eliminating the need for self-injection equipment and offering a more accessible treatment experience. Its second program, KVD824, extends the oral approach to prophylaxis, potentially replacing injectable regimens for chronic attack prevention.

Sebetralstat is an oral, small molecule plasma kallikrein inhibitor designed for on-demand treatment of acute HAE attacks. It advanced through Phase III development in the KONFIDENT trial, a randomized, placebo-controlled global study evaluating time to symptom relief and attack severity outcomes. Sebetralstat was notable as the first oral on-demand candidate to reach Phase III in HAE, a milestone that attracted significant investor and industry attention and ultimately contributed to Chiesi's acquisition interest.

KalVista's pipeline is anchored in HAE, with sebetralstat targeting acute attacks and KVD824 addressing prophylaxis, but the company's origins lie in ophthalmology, specifically diabetic macular edema driven by retinal kallikrein pathway dysregulation. Early-stage intravitreal plasma kallikrein inhibitor work continues as a secondary program area, leveraging the same mechanistic expertise developed for the systemic HAE franchise. The pipeline is therefore defined by plasma kallikrein biology across two organ systems rather than by broad therapeutic diversification.

KalVista is a late-stage clinical company, with sebetralstat having completed Phase III evaluation in HAE and KVD824 in earlier clinical development for prophylaxis. Pending the close of the Chiesi acquisition, regulatory submission and review for sebetralstat represent the key remaining steps before potential commercialization. The transition from standalone Nasdaq-listed entity to Chiesi subsidiary will likely shape how and when regulatory filings are pursued across major markets including the US and Europe.

KalVista's near-term outlook is shaped by several converging factors following the Chiesi acquisition announcement:

Want to Update your Company's Profile?